ADAR

Across TCGA pan-cancer cohorts, ADAR mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADAR data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ADAR mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ADAR expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, HNSC, and COAD are the cancer types where ADAR mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.738	0.230	.003	34	view →
HNSC	OS	Tertile	IV	0.620	0.867	.006	22	view →
COAD	DFS	Tertile	II,III,IV	0.904	1.000	.041	18	view →
LSCC	DFS	Median	All	0.991	0.560	.016	8	view →
CCRCC	OS	Tertile	All	0.931	1.000	.039	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ADAR–LUAD (DFS)

Open the LUAD breakdown →